Moderna has initiated a purchase from Jefferies, to be added to the Nasdaq 100


Modern (MRNA) – Get a report rose after Jefferies analyst Michael Yee started covering the biopharmaceutical company with a purchase price and price target of $ 90, and Nasdaq has stated that it will add the stock to the Nasdaq 100.The company’s coronavirus vaccine candidate could sell for up to $ 5 billion a year, he wrote in a comment quoted by Bloomberg.

Moderna said last week that it had completed enrolling patients in a phase II study of the vaccine candidate, mRNA-1273.

Moderna is one of hundreds of companies looking for an effective vaccine. In May, the Cambridge, Massachusetts-based company said the results of its phase I study were positive.


Please enter your comment!
Please enter your name here